CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Charles River Laboratories International, Inc.

Equities

CRL

US1598641074

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:02 2024-07-12 pm EDT			5-day change	1st Jan Change
216.2 ^USD	+2.52%		+8.28%	-8.55%

Jul. 10	Baird Adjusts Price Target on Charles River Laboratories International to $239 From $271	MT
Jul. 08	Charles River Laboratories International, Inc. and AAVantgarde Announces Contract Development and Manufacturing Organization Agreement to Produce Good Manufacturing Practice	CI

Charles River Laboratories : Charles River to Present at J.P. Morgan Healthcare Conference

January 09, 2012 at 08:35 am EST

MarketScreener.com By

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the J.P. Morgan 30^th Annual Healthcare Conference in San Francisco, California on Wednesday, January 11^th, at 8:30 a.m. PST (11:30 a.m. EST). Management will present an overview of Charles River's strategic focus and business developments.

A live webcast of the presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at http://ir.criver.com. A webcast replay will be accessible through the same website approximately three hours after the presentation and will remain available through January 25, 2012.

Charles River Laboratories International, Inc.
Investor Relations Contact:
Susan E. Hardy, 781-222-6190
Corporate Vice President, Investor Relations

Latest news about Charles River Laboratories International, Inc.

Baird Adjusts Price Target on Charles River Laboratories International to $239 From $271	Jul. 10	MT
Charles River Laboratories International, Inc. and AAVantgarde Announces Contract Development and Manufacturing Organization Agreement to Produce Good Manufacturing Practice	Jul. 08	CI
Argus Downgrades Charles River Laboratories International to Hold From Buy	Jun. 28	MT
Charles River Laboratories, Gates Institute Collaborate on Lentiviral Vector Manufacturing	Jun. 25	MT
Charles River Laboratories Announces Strategic Lentiviral Vector Manufacturing Collaboration with Gates Institute at University of Colorado Anschutz Medical Campus	Jun. 25	CI
Charles River Laboratories, Captain T Cell Enter Manufacturing Deal	Jun. 17	MT
Charles River Laboratories International, Inc and Captain T Cell Announce Plasmid DNA and Viral Vector Manufacturing Alliance for Gene-Modified Cell Therapy	Jun. 17	CI
Baird Adjusts Price Target on Charles River Laboratories International to $271 From $270	Jun. 13	MT
The job report just threw a spanner in the works	Jun. 07
Mizuho Initiates Charles River Laboratories International With Neutral Rating, $235 Price Target	Jun. 07	MT
ANALYST RECOMMENDATIONS : Lyft, Amazon, Fedex, Xpo, Unilever...	Jun. 07
Charles River Laboratories Opens New Contract Vivarium Space in Massachusetts	Jun. 06	MT
The first rate cut	Jun. 06
Charles River Laboratories Expands Access to CRADL® Contract Vivarium Space in Somerville	Jun. 06	CI
ANALYST RECOMMENDATIONS : American Airlines, Salesforce, Five Below, Tesla, Okta...	Jun. 06
Transcript : Charles River Laboratories International, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 10:00 AM	Jun. 05
Transcript : Charles River Laboratories International, Inc. Presents at The 44th Annual William Blair Growth Stock Conference, Jun-04-2024 10:00 AM	Jun. 04
Charles River Laboratories, Sanofi Collaborating to Develop Non-Animal Virtual Control Groups for Preclinical Trials	Jun. 04	MT
Charles River Laboratories International, Inc. Launches Viral Vector Tech Transfer Program to Safeguard Gene Therapy Development	May. 30	CI
Transcript : Charles River Laboratories International, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:00 AM	May. 15
TD Cowen Adjusts Price Target on Charles River Laboratories International to $228 From $260	May. 13	MT
Declaration of Voting Results of Charles River Laboratories International Inc	May. 10	CI
JPMorgan Adjusts Price Target on Charles River Laboratories International to $270 From $280	May. 10	MT
Jefferies Adjusts Price Target on Charles River Laboratories International to $226 From $235	May. 10	MT
Evercore ISI Adjusts Price Target on Charles River Laboratories International to $265 From $300	May. 10	MT

Chart Charles River Laboratories International, Inc.

Duration

Period

Chart Charles River Laboratories International, Inc.

More charts

Company Profile

Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (63.4%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development and sale of research models and related services (19.2%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ; - development of solutions used in drug manufacturing processes (17.5%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies. Net sales break down by source of income between sales of services (83.3%) and sales of products (16.7%). Net sales are distributed geographically as follows: the United States (56.8%), Europe (26%), Canada (11.8%), Asia/Pacific (4.9%) and other (0.4%).

Sector

Biotechnology & Medical Research

Calendar

2024-07-30 - Q2 2024 Earnings Release (Projected)

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Charles River Laboratories International, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

216.2 USD

Average target price

259 USD

Spread / Average Target

+19.82%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-8.55%	11.14B
MODERNA, INC.	+22.10%	46.55B
LONZA GROUP AG	+46.45%	41.84B
IQVIA HOLDINGS INC.	-3.12%	40.84B
ALNYLAM PHARMACEUTICALS, INC.	+36.10%	32.95B
CELLTRION, INC.	-6.30%	28.27B
ICON PUBLIC LIMITED COMPANY	+18.71%	27.78B
UNITED THERAPEUTICS CORPORATION	+46.15%	14.26B
MEDPACE HOLDINGS, INC.	+44.52%	13.69B
BIO-TECHNE CORPORATION	+0.19%	12.18B

Other Biotechnology & Medical Research